Andrew Abramowitz is a partner in the Firm’s domestic and international securities practice. His practice focuses on investor protection issues, including litigation under federal securities law, state law governing fiduciary duties, and ERISA.
Mr. Abramowitz has served as one of the lead counsel in numerous cases under the federal securities laws and state laws governing fiduciary duties. Recent cases include In re Abbott Depakote Shareholder Derivative Litigation, No. 11 Civ. 08114 (VMK) (N.D. Ill.); In re Life Partners Holdings, Inc. Derivative Litigation, C.A. No. 2:11-CV-00043-AM (W.D. Tex.); Scandlon v. Blue Coat Systems, Inc., No. CV 11-04293 (RS) (N.D. Cal.); In re Synthes Inc. Shareholder Litigation, C.A. No. 6452-CS (Del. Ch.); and Utah Retirement Systems v. Strauss, et al., No. 09 Civ. 3221(TCP)(ETB) (E.D.N.Y.) (American Home Mortgage, Inc.). Notably, in In re Atheros Communications, Inc. Shareholder Litigation, C.A. No. 6124-VCN (Del. Ch.), Mr. Abramowitz was on the team whose efforts secured a preliminary injunction that halted the shareholder vote on Qualcomm Incorporated's proposed $3.1 billion acquisition of Atheros Communications, Inc. until shareholders were provided with additional material information regarding the merger. He also represented lead plaintiffs in In re Parmalat Securities Litigation, No. 04 Civ. 0030 (LAK) (S.D.N.Y.), often called the “Enron of Europe,” which was a massive worldwide securities fraud action involving the collapse of an international dairy conglomerate.
